https://orcid.org/0000-0002-2390-6505
References
- Marzano AV, Damiani G, Ceccherini I, et al. Autoinflammation in pyoderma gangrenosum and its syndromic form (pyoderma gangrenosum, acne and suppurative hidradenitis). Br J Dermatol. 2017;176(6):1588–1598.
- Marzano AV, Fanoni D, Antiga E, et al. Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet's syndrome. Clin Exp Immunol. 2014;178(1):48–56.
- Braswell SF, Kostopoulos TC, Ortega-Loayza AG. Pathophysiology of pyoderma gangrenosum (PG): an updated review. J Am Acad Dermatol. 2015;73(4):691–698.
- Kridin K, Cohen AD, Amber KT. Underlying systemic diseases in pyoderma gangrenosum: a systematic review and meta-analysis. Am J Clin Dermatol. 2018;19(4):479–487.
- Ott C, Takses A, Obermeier F, et al. Smoking increases the risk of extraintestinal manifestations in Crohn’s disease. World J Gastroenterol. 2014;20(34):12269–12276.
- States V, O’Brien S, Rai JP, et al. Pyoderma gangrenosum in inflammatory bowel disease: a systematic review and meta-analysis. Dig Dis Sci. 2020. DOI:10.1007/s10620-019-05999-4
- Cohen AD, Dreiher J, Regev-Rosenberg S, et al. The quality indigators program in Clalit Health Services: the first decade. Harefuah. 2010;149(4):204–265.
- Rennert G, Peterburg Y. Prevalence of selected chronic diseases in Israel. Isr Med Assoc J. 2001;3(6):404–408.
- Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
- Zvidi I, Hazazi R, Birkenfeld S, et al. The prevalence of Crohn’s disease in Israel: A 20-Year survey. Dig Dis Sci. 2009;54(4):848–852.
- Greenland S, Thomas DC. On the need for the rare disease assumption in case-control studies. Am J Epidemiol. 1982;116(3):547–553.
- Polcz M, Gu J, Florin T. Pyoderma gangrenosum in inflammatory bowel disease: The experience at Mater Health Services’ Adult Hospital. J Crohn’s Colitis. 2011;5(2):148–151.
- Weizman AV, Huang B, Targan S, et al. Pyoderma gangrenosum among patients with inflammatory bowel disease: a descriptive cohort study. J Cutan Med Surg. 2015;19(2):125–131.
- Farhi D, Cosnes J, Zizi N, et al. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients. Medicine (Baltimore). 2008;87(5):281–293.
- Nguyen GC, Torres EA, Regueiro M, et al. Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic whites: Characterization of a large North American cohort. Am J Gastroenterol. 2006;101(5):1012–1023.
- Mahamid M, Bar-Gil Shitrit A, Amara H, et al. Ethnic variations in inflammatory bowel diseases among Israel’s populations. Isr Med Assoc J. 2019;21(10):662–665.
- Kenny EE, Pe'er I, Karban A, et al. A genome-wide scan of Ashkenazi Jewish Crohn’s disease suggests novel susceptibility loci. PLoS Genet. 2012;8(3):e1002559.
- Rivas MA, Avila BE, Koskela J, International IBD Genetics Consortium, et al. Insights into the genetic epidemiology of Crohn’s and rare diseases in the Ashkenazi Jewish population. PLoS Genet. 2018;14(5):e1007329.
- Roberts H, Rai SN, Pan J, et al. Extraintestinal manifestations of inflammatory bowel disease and the influence of smoking. Digestion. 2014;90(2):122–129.
- Karmiris K, Avgerinos A, Tavernaraki A, et al. Prevalence and characteristics of extra-intestinal manifestations in a large cohort of Greek patients with inflammatory bowel disease. J Crohn’s Colitis. 2016;10(4):429–436.
- Manguso F, Sanges M, Staiano T, et al. Cigarette smoking and appendectomy are risk factors for extraintestinal manifestations in ulcerative colitis. Am J Gastroenterol. 2004;99(2):327–334.
- Parkes GC, Whelan K, Lindsay JO. Smoking in inflammatory bowel disease: Impact on disease course and insights into the aetiology of its effect. J Crohns Colitis. 2014;8(8):717–725.
- Höfler M. The Bradford Hill considerations on causality: a counterfactual perspective. Emerg Themes Epidemiol. 2005; 2:11.